MAGEA13P: A Potential Drug Target and Biomarker (G139363)

Target Name: MAGEA13P

NCBI ID: G139363

MAGEA13P

Other Name(s): MAGE family member A13, pseudogene | Melanoma antigen family A13, pseudogene

MAGEA13P: A Potential Drug Target and Biomarker

MAGEA13P, a member of the MAGE family of cytoskeletal proteins, has been identified as a potential drug target and biomarker. The MAGE family plays a crucial role in the development and maintenance of tissue structure and mechanics, and MAGEA13P has been shown to regulate cell migration, invasion, and metastasis.

MAGEA13P: Structure and Function

The MAGEA13P protein is a 13-kDa protein that belongs to the MAGEA subfamily of cytoskeletal proteins. These proteins are involved in the regulation of cell adhesion, migration, and invasion, and are characterized by the presence of a characteristic domain that includes a leucine-rich repeat (LRR) and a short proline-rich sequence (PR).

MAGEA13P is expressed in a variety of tissues, including muscle, bone, and skin, and has been shown to play a role in the regulation of cell migration, invasion, and metastasis. For example, studies have shown that MAGEA13P can promote the migration of cancer cells by increasing the mobility of cell tracks and by inhibiting the formation of tight junctions between adjacent cells.

In addition to its role in cell migration, MAGEA13P has also been shown to be involved in the regulation of cell adhesion. Studies have shown that MAGEA13P can interact with the adhesion molecule E-cadherin and that this interaction can influence the distribution of cadherins in the cytoskeleton.

MAGEA13P: Potential Drug Target

The potential drug target for MAGEA13P is its role in cell migration and invasion, which make it an attractive target for small molecule inhibitors. Studies have shown that MAGEA13P is sensitive to inhibitors of its LRR and PR domains, and that these inhibitors can inhibit its cell migration and invasion.

In addition to its sensitivity to small molecule inhibitors, MAGEA13P is also a good candidate for a drug target because of its well-established role in the regulation of cell adhesion. MAGEA13P has been shown to interact with several adhesion molecules, including E-cadherin, N-cadherin, and vimentin, and the regulation of these interactions may be important for the development of cancer.

MAGEA13P: Biomarker

MAGEA13P has also been identified as a potential biomarker for several types of cancer, including breast, ovarian, and prostate cancer. The regulation of MAGEA13P has been shown to be altered in these cancers, and the levels of MAGEA13P have been shown to be elevated in the cells of patients with these cancers.

In addition to its potential as a biomarker, MAGEA13P has also been shown to be involved in the regulation of cell cycle progression, and the regulation of cell cycle progression may be important for the development and maintenance of cancer. Studies have shown that MAGEA13P can inhibit the G1 phase of the cell cycle and that this inhibition can lead to the accumulation of mutations in the DNA.

Conclusion

MAGEA13P is a member of the MAGEA family of cytoskeletal proteins that has been shown to play a role in the regulation of cell migration, invasion, and metastasis. The potential drug target for MAGEA13P is its role in cell migration and invasion, and the biomarker it has been shown to be involved in the regulation of cell cycle progression. Further studies are needed to fully understand the role of MAGEA13P in the development and maintenance of cancer.

Protein Name: MAGE Family Member A13, Pseudogene

The "MAGEA13P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEA13P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets